TREAT (2009) — Trial Summary
TREAT (2009): Darbepoetin alfa did not reduce the risk of death, cardiovascular events, or renal events in patients with type 2 diabetes, CKD, and anemia, and was associated with an increased risk of stroke.
References
- Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.